The Polymyalgia Rheumatica (PMR) drugs in development market research report provides comprehensive information on the therapeutics under development for Polymyalgia Rheumatica (PMR), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Polymyalgia Rheumatica (PMR). Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Polymyalgia Rheumatica (PMR) and features dormant and discontinued products.
GlobalData tracks six drugs in development for Polymyalgia Rheumatica (PMR) by six companies/universities/institutes. The top development phase for Polymyalgia Rheumatica (PMR) is phase ii with three drugs in that stage. The Polymyalgia Rheumatica (PMR) pipeline has six drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Polymyalgia Rheumatica (PMR) pipeline products market are: Biogen, F. Hoffmann-La Roche and Novartis.
The key targets in the Polymyalgia Rheumatica (PMR) pipeline products market include Interleukin 6 Receptor Subunit Alpha, Interleukin 17A, and Glucocorticoid Receptor.
The key mechanisms of action in the Polymyalgia Rheumatica (PMR) pipeline product include Glucocorticoid Receptor Agonist with one drug in Phase II. The Polymyalgia Rheumatica (PMR) pipeline products include five routes of administration with the top ROA being Intravenous and two key molecule types in the Polymyalgia Rheumatica (PMR) pipeline products market including Monoclonal Antibody, and Small Molecule.
Polymyalgia Rheumatica (PMR) overview
Polymyalgia rheumatica (PMR) is a rheumatic disorder characterized by pain and stiffness around the neck, shoulder, and hip area. This disorder is more common in white adults over 50 years of age. It is an inflammatory condition associated with an elevation of erythrocyte sedimentation rate (ESR) and c-reactive protein (CRP).
For a complete picture of Polymyalgia Rheumatica (PMR)’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
